^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

PRCP (Prolylcarboxypeptidase)

i
Other names: PRCP, Prolylcarboxypeptidase, PCP, Angiotensinase C, HUMPCP, Lysosomal Pro-X Carboxypeptidase, Lysosomal Carboxypeptidase C, Proline Carboxypeptidase, Prolylcarboxypeptidase (Angiotensinase C)
Associations
Trials
4ms
Patient and physician preferences among colorectal cancer screening tests: updated predictions from a discrete choice experiment. (PubMed, Curr Med Res Opin)
US adults eligible for CRC screening preferred mt-sDNA testing over other screening modalities, while physicians highly preferred colonoscopy. Offering CRC screening options that align with patient preferences may result in higher screening adherence.
Journal
|
PRCP (Prolylcarboxypeptidase)
10ms
Nutrigenomic insights and cardiovascular benefits of blackberry (Rubus ulmifolius Schott.) and mugwort (Artemisia campestris L.). (PubMed, Exp Physiol)
A dose-dependent hypotensive effect and a carbachol-like vasodilatory effect were observed for blackberry and compared with those of mugwort...Chlorogenic acids, quercetin and kaempferol derivatives were identified in blackberry as the main bioactive molecules likely to be responsible for its cardiovascular effect. The blackberry extract exhibited a vasorelaxant effect 20 times greater than mugwort, attributed to the exclusive presence of the hypotensive galloyl-bis-HHDP glucose derivative and a more pronounced upregulation of Tfcp2l1, which is involved in epithelial cell maturation. This study validates the traditional use of blackberry and mugwort in treatment of hypertension, identifies marker genes and bioactive molecules for vasodilatory and hypotensive effects and expands their potential applications to cancer prevention, inflammation reduction and appetite regulation.
Journal
|
CDH1 (Cadherin 1) • PRCP (Prolylcarboxypeptidase)
|
chlorogenic acid
over3years
Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer. (PubMed, Cancer Biol Ther)
We previously found PRCP overexpression promoted 4-hydroxytamoxifen (4-OHT) resistance in estrogen receptor-positive (ER+) breast cancer cells...We found PRCP increased IGF1R/HER3 signaling and AKT activation in ER+ breast cancer cells that was blocked by PRCPi. Thus, PRCP is an adverse prognostic marker in breast cancer and a potential target to improve endocrine therapy in ER+ breast cancers.
Journal
|
ER (Estrogen receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • PRCP (Prolylcarboxypeptidase)
|
ER positive
|
tamoxifen